SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-057569
Filing Date
2024-07-01
Accepted
2024-07-01 08:09:37
Documents
9
Period of Report
2024-07-01

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0208723-6k_nlspharma.htm 6-K 22154
2 FORM OF COMMON WARRANT ea020872301ex4-1_nlspharma.htm EX-4.1 88700
3 FORM OF SERIES A PLACEMENT AGENT WARRANT ea020872301ex4-2_nlspharma.htm EX-4.2 88920
4 FORM OF SERIES B PLACEMENT AGENT WARRANT ea020872301ex4-3_nlspharma.htm EX-4.3 89030
5 OPINION OF WENGER VIELI AG, SWISS COUNSEL TO NLS PHARMACEUTICS LTD ea020872301ex5-1_nlspharma.htm EX-5.1 25275
6 FORM OF SECURITIES PURCHASE AGREEMENT, DATED JUNE 28, 2024, BY AND BETWEEN NLS P ea020872301ex10-1_nlspharma.htm EX-10.1 260620
7 PRESS RELEASE TITLED: "NLS PHARMACEUTICS ANNOUNCES REGISTERED DIRECT OFFERING" ea020872301ex99-1_nlspharma.htm EX-99.1 15159
8 GRAPHIC ex5-1_001.jpg GRAPHIC 7710
9 GRAPHIC ex99-1_001.jpg GRAPHIC 16764
  Complete submission text file 0001213900-24-057569.txt   624896
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 241088236
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)